Brabo, the problem with your analysis is not the result but of the comparison. There are only three main areas of potential short term sales right now. The US(no FDA approval yet), the strong European Union countries (Failed previous UK launch in past due to product quality, since fixed, no insurance approval yet which in socialized med countries make a larger difference, and a price level too high), or Japan/Brazil (Japan still has a few issues outstanding and Brazil had pricing issues). Besides the US the main other issues from market test was the price, hence the reason they have gone to a different product battery strength along with packaging to be able to get in the more competitive price range. They have done a lot of work on this that should be acknowledged as a plus not a minus. So your statement of two years and with low sales growth while a valid point, does not take into consideration all the changes in the last two years. If I was them I would have slowed the Canadian launch if I felt that US was close as they do so I could use my resources wisely.
News 
Market Data 
Discover 
AI
